Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

NCT02873819 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Oral Cavity

Interventions

DRUG: GL-0817
DRUG: Hiltonol
DRUG: Sargramostim
DRUG: cyclophosphamide
DRUG: Placebo

Sponsor

Gliknik Inc.